دوشنبه 10 دی 1403
[Archive]
دوره 29، شماره 136 - ( 6-1400 )
جلد 29 شماره 136 صفحات 292-286 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Naderi Nabi B, Saberi A, Bakhshayesh Eghbali B, Hosseininezhad M, Biazar G, Abbasi Malekabadi A et al . Efficacy and Safety of TENS and Duloxetine in Patients with Painful Diabetic Neuropathy: A Single Blind Randomized Clinical Trial. J Adv Med Biomed Res 2021; 29 (136) :286-292
URL: http://journal.zums.ac.ir/article-1-6193-fa.html
URL: http://journal.zums.ac.ir/article-1-6193-fa.html
Efficacy and Safety of TENS and Duloxetine in Patients with Painful Diabetic Neuropathy: A Single Blind Randomized Clinical Trial. Journal of Advances in Medical and Biomedical Research. 1400; 29 (136) :286-292
چکیده: (135104 مشاهده)
Background and Objective: Both duloxetine (DLX) and transcutaneous electrical nerve stimulation (TENS) are recommended as safe and effective treatments for diabetic peripheral neuropathic pain. However, these methods have not been compared. This study aimed to compare the efficacy of treatment by DLX and TENS in diabetic neuropathy pain relief.
Materials and Methods: This survey was performed on 60 eligible diabetic patients randomly divided into two groups of DLX (20, 40, and 60 mg/day for weeks 1, 2, and 3-12, respectively), and TENS (20 min,80 HZ, 50 Amp, 0.2 ms Square pulses 2-3 times sensory threshold). The participants were evaluated according to the numerical rating scale (NRS) after four and twelve weeks of treatment. Moreover, adverse drug reactions were documented during the study period.
Results: Baseline demographic data had no significant difference between the two groups (P≥0.05). The average NRS scores were significantly lower in the DLX group in both measurement times. At the end of weeks four (P=0.01) and 12 (P=0.001), the trend of changes was significant from baseline to the third month (P=0.0001). No patient in the TENS group reported any side effects, while 18% did in the DLX group.
Conclusion: We found that both DLX and TENS were effective and safe for the management of painful diabetic neuropathy. The DLX seemed to be better, compared to TENS. However, in some conditions, such as drug intolerance or contraindication for medications, TENS could be a proper intervention.
Materials and Methods: This survey was performed on 60 eligible diabetic patients randomly divided into two groups of DLX (20, 40, and 60 mg/day for weeks 1, 2, and 3-12, respectively), and TENS (20 min,80 HZ, 50 Amp, 0.2 ms Square pulses 2-3 times sensory threshold). The participants were evaluated according to the numerical rating scale (NRS) after four and twelve weeks of treatment. Moreover, adverse drug reactions were documented during the study period.
Results: Baseline demographic data had no significant difference between the two groups (P≥0.05). The average NRS scores were significantly lower in the DLX group in both measurement times. At the end of weeks four (P=0.01) and 12 (P=0.001), the trend of changes was significant from baseline to the third month (P=0.0001). No patient in the TENS group reported any side effects, while 18% did in the DLX group.
Conclusion: We found that both DLX and TENS were effective and safe for the management of painful diabetic neuropathy. The DLX seemed to be better, compared to TENS. However, in some conditions, such as drug intolerance or contraindication for medications, TENS could be a proper intervention.
نوع مطالعه: کارآزمایی بالینی |
موضوع مقاله:
Health improvement strategies
دریافت: 1399/6/11 | پذیرش: 1399/10/8 | انتشار: 1400/1/15
دریافت: 1399/6/11 | پذیرش: 1399/10/8 | انتشار: 1400/1/15
فهرست منابع
1. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11(6):521-34. [DOI:10.1016/S1474-4422(12)70065-0]
2. Khdour MR. Treatment of diabetic peripheral neuropathy: a review. J Pharm Pharmacol. 2020;72(7):863-72. [DOI:10.1111/jphp.13241]
3. Austin PJ, Moalem-Taylor G. The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. J Neuroimmunol. 2010;229(1-2):26-50. [DOI:10.1016/j.jneuroim.2010.08.013]
4. Tawfik MK, Helmy SA, Badran DI, Zaitone SA. Neuroprotective effect of duloxetine in a mouse model of diabetic neuropathy: role of glia suppressing mechanisms. Life Sci. 2018;205:113-24. [DOI:10.1016/j.lfs.2018.05.025]
5. Zakerkish M, Raeisi D, Rafie S, et al. Comparison of efficacy of nortriptyline versus transcutaneous electrical nerve stimulation on painful peripheral neuropathy in patients with diabetes. Romanian J Diabet Nutr Metab Dis. 2019;26(4):401-11. [DOI:10.2478/rjdnmd-2019-0043]
6. Gomar A, Hosseini A, Mirazi N, Gomar M. Effect of hydroethanolic extract of Rubus fruticosus on neuropathic pain in wistar diabetic rats. Caspian J Neurol Sci. 2015;1(1):27-34. [DOI:10.18869/acadpub.cjns.1.1.27]
7. Lyman D. B cell therapy to treat an axonal neuropathy in mixed connective tissue disease. Caspian J Neurol Sci. 2017;3(1):46-53. [DOI:10.18869/acadpub.cjns.3.8.46]
8. Gewandter JS, Chaudari J, Ibegbu C, et al. Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study. Support Care Cancer. 2019;27(5):1765-74. [DOI:10.1007/s00520-018-4424-6]
9. Gibson W, Wand BM, O'Connell NE. Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults. Coch Database Sys Rev. 2017 (9). [DOI:10.1002/14651858.CD011976.pub2]
10. Ogle T, Alexander K, Miaskowski C, Yates P. Systematic review of the effectiveness of self-initiated interventions to decrease pain and sensory disturbances associated with peripheral neuropathy. J Cancer Survivorship. 2020;14:444-64. [DOI:10.1007/s11764-020-00861-3]
11. Mokhtari T, Ren Q, Li N, Wang F, Bi Y, Hu L. Transcutaneous electrical nerve stimulation in relieving neuropathic pain: basic mechanisms and clinical applications. Curr Pain Headache Rep. 2020 ; 24(4): 14 p.Available from: http://europepmc.org/abstract/MED/32072323 [DOI:10.1007/s11916-020-0846-1]
12. Majdinasab N, Kaveyani H, Azizi M. A comparative double-blind randomized study on the effectiveness of duloxetine and gabapentin on painful diabetic peripheral polyneuropathy. Drug Design Develop Ther. 2019;13:1985. [DOI:10.2147/DDDT.S185995]
13. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461-98. [DOI:10.1007/s00125-018-4729-5]
14. Herman W, Pop‐Busui R, Braffett B, et al. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the diabetes control and complications trial/epidemiology of diabetes interventions and complications. Diabet Med. 2012;29(7):937-44. [DOI:10.1111/j.1464-5491.2012.03644.x]
15. Snyder MJ, Gibbs LM, Lindsay TJ. Treating painful diabetic peripheral neuropathy: an update. Am Fam Physic. 2016;94(3):227-34.
16. Javeed A, Alam MA, Maqsood A, Azher A, Arif M, Qayyum A. Comparison of efficacy of duloxetine with amitriptyline in terms of reduction in frequency of pain in the patients of diabetic neuropathy. Prof Med J. 2020;27(09):1891-4. [DOI:10.29309/TPMJ/2020.27.09.4289]
17. Joharchi K, Memari M, Azargashb E, Saadat N. Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial. J Diabet Metab Disorder. 2019;18(2):575-82. [DOI:10.1007/s40200-019-00427-w]
18. Devi P, Madhu K, Ganapathy B, Sarma G, John L, Kulkarni C. Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy. Indian J Pharmacol. 2012;44(1):51. [DOI:10.4103/0253-7613.91867]
19. Yasuda H, Hotta N, Kasuga M, Yamada T, et al. Efficacy and safety of 40 mg or 60 mg duloxetine in J apanese adults with diabetic neuropathic pain: Results from a randomized, 52‐week, open‐label study. J Diabet Invest. 2016;7(1):100-8. [DOI:10.1111/jdi.12361]
20. Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med. 2006;7(5):373-85. [DOI:10.1111/j.1526-4637.2006.00207.x]
21. Happich M, Schneider E, Boess FG, et al. Effectiveness of duloxetine compared with pregabalin and gabapentin in diabetic peripheral neuropathic pain: results from a German observational study. Clin J Pain. 2014;30(10):875-85. [DOI:10.1097/AJP.0000000000000057]
22. Boyle J, Eriksson ME, Gribble L, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabet Care. 2012;35(12):2451-8. [DOI:10.2337/dc12-0656]
23. Sun P, Zhao Y, Zhao Z, Bernauer M, Watson P. Dosing pattern comparison between duloxetine and pregabalin among patients with diabetic peripheral neuropathic pain. Pain Pract. 2012;12(8):641-8. [DOI:10.1111/j.1533-2500.2012.00537.x]
24. Nabi BN, Sedighinejad A, Haghighi M, et al. Comparison of transcutaneous electrical nerve stimulation and pulsed radiofrequency sympathectomy for treating painful diabetic neuropathy. Anesthesiol Pain Med. 2015;5(5). [DOI:10.5812/aapm.29280]
25. Yadav AO, Ramteke G. Effectiveness of transcutaneous electrical nerve stimulator (TENS) in reducing neuropathic pain in patients with diabetic neuropathy. Indian J Physiother Occup Ther. 2013;7(1):11.
26. Oyibo S, Breislin K, Boulton A. Electrical stimulation therapy through stocking electrodes for painful diabetic neuropathy: a double blind, controlled crossover study. Diabet Med. 2004;21(8):940-4. [DOI:10.1111/j.1464-5491.2004.01243.x]
27. Alomar MJ. Factors affecting the development of adverse drug reactions. Saudi Pharmaceut J. 2014;22(2):83-94. [DOI:10.1016/j.jsps.2013.02.003]
28. Bushra R, Aslam N, Khan AY. Food-drug interactions. Oman Med J. 2011;26(2):77. [DOI:10.5001/omj.2011.21]
29. Fox MA, Jensen CL, Gallagher PS, Murphy DL. Receptor mediation of exaggerated responses to serotonin-enhancing drugs in serotonin transporter (SERT)-deficient mice. Neuropharmacol. 2007;53(5):643-56. [DOI:10.1016/j.neuropharm.2007.07.009]
30. Bagheri A, Kamalidehghan B, Haghshenas M, et al. Prevalence of the CYP2D6* 10 (C100T),* 4 (G1846A), and* 14 (G1758A) alleles among Iranians of different ethnicities. Drug Des, Devel Ther. 2015;9:2627. [DOI:10.2147/DDDT.S79709]
31. Razazian N, Baziyar M, Moradian N, Afshari D, Bostani A, Mahmoodi M. Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy: a randomized, double-blind trial. Neurosci. 2014;19(3):192.
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
